

from
(a) selecting an antibody that targets a specific binding sites on a tumor cell;

(b) selecting an alpha particle-emitting isotope;

OK
(c) selecting a value for a high specific activity for an alpha particle-emitting isotope/antibody construct from a range of specific activities, said construct comprising said isotope conjugated to said antibody via a bifunctional chelant; *? Jack new matter? p. 32*

B. still need check for mass w/ly.
wherein said range of specific activities is such that the value selected is at least sufficient for a pharmacologically effective amount of a dose of said construct to provide an amount of antibody to bind to a plurality of targeted sites on the tumor cell wherein ^{<<}at least one alpha track^{>>} per tumor cell is delivered thereto from said isotope upon binding of the antibody;

*1.16
line 1-13
p. 31
line 3-4*
(d) systemically administering the dose of said high specific activity construct to said human, wherein the size of the tumor is reduced; and *U*

(e) repeating step (d) wherein each repetition further reduces the size of the tumor thereby killing the tumor.

+ have marked correct version

Please amend claim 4 to read as follows:

B²
4. (twice-amended) The method of claim 1, wherein
said range of high specific activity is about 0.1 mCi/mg to about 30
mCi/mg.

Please amend claim 7 to read as follows:

B³
7. (twice-amended) The method of claim 1, wherein
said dose is from about 0.1 mg/m² to about 25 mg/m². *new matter?*
Yes.

Please cancel claim 5.

no specific 25 mg/m²

REMARKS

Status of the Claims

Claims 1, 3-5 and 7 are pending. Claims 1, 3-5 and 7 stand rejected. Claims 1, 4 and 7 are amended herein. Claim 5 is canceled. No new matter has been added.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendments. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE". No new matter has been added.